China-focused venture capital firm Qiming Venture Partners has led a RMB200 million (US$29 million) series A round in Sino Biological Inc., a Beijing-based recombinant protein and antibody developer, according to a company announcement.
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access Over 11,000 stories and data posts over the past 8 years!
Register NowAlready have an account or paid subscription? Log in
